IFNA6 (interferon alpha 6) is a type I interferon that plays specialized roles in antiviral immunity and immune system regulation. The protein functions as a cytokine with antiviral activities and is involved in multiple immune pathways including B cell activation, T cell activation, and natural killer cell activation 1. IFNA6 demonstrates unique mechanistic properties distinct from other interferon subtypes. In COVID-19 patients, IFNA6 specifically associates with proteomics signatures indicative of endothelial damage and platelet activation, contrasting with other interferons that primarily drive antiviral transcriptional responses 2. The gene shows differential expression patterns in various disease contexts - it is downregulated in pulmonary embolism patients and external genital warts treated with sinecatechins 13, while being upregulated during SARS-CoV-2 infection 4. IFNA6 demonstrates potent antiviral efficacy, particularly against influenza virus, where it reduces lung viral replication and enhances immune responses when used in DNA vaccination strategies 5. Additionally, IFNA6 has been identified as a melanoma susceptibility gene through genome-wide association studies, suggesting broader roles in disease pathogenesis 6. The protein can be induced by various stimuli including imiquimod and viral infections through signal transduction pathways involving tyrosine kinase and protein kinase C 7.